C-peptide vs BI 456906
Head-to-head comparison of C-peptide (Connecting peptide (C-peptide)) and BI 456906 (BI 456906, glucagon-like peptide-1/glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
| Property | C-peptide | BI 456906 |
|---|---|---|
| Category | Pain Management | Weight Management |
| Full Name | Connecting peptide (C-peptide) | BI 456906, glucagon-like peptide-1/glucagon receptor dual agonist |
| Molecular Weight | 3020.3 Da | N/A |
| Half-Life | ~20-30 min | Approximately 1 week |
| Amino Acids | 31 | N/A |
| Typical Dose | no approved analgesic dose|research-only | Trial-dependent; weekly SC dosing |
| Route | IV|subQ | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 46 | 10 |
| Research Status | Pre-clinical | Clinical |
C-peptide Benefits
- ✓diabetic neuropathy research
- ✓nerve function support
- ✓possible analgesic effect
BI 456906 Benefits
- ✓weight reduction
- ✓improved glucose control
- ✓lower liver-fat burden
- ✓enhanced satiety
C-peptide Dosing
0.5-1.0 mg/day in research|route varies by protocol
BI 456906 Dosing
once-weekly subcutaneous injection|stepwise titration|ongoing maintenance phase
C-peptide Side Effects
- ⚠injection-site reactions
- ⚠unknown long-term safety
BI 456906 Side Effects
- ⚠nausea
- ⚠abdominal discomfort
- ⚠diarrhea
Research Overview
C-peptide
C-peptide is not an approved analgesic, but multiple studies have examined its effects on peripheral nerve blood flow and neuropathy outcomes. The strongest relevance is in diabetic neuropathic pain rather than migraine.
BI 456906
Preclinical and early clinical research support meaningful metabolic effects with a tolerable safety profile. It remains investigational and is not commercially available.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.